TransMedics Group (NASDAQ:TMDX) Price Target Raised to $125.00 at Oppenheimer

TransMedics Group (NASDAQ:TMDX) had its price target hoisted by Oppenheimer from $105.00 to $125.00 in a research report report published on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other equities analysts have also recently issued reports about the company. Morgan Stanley lifted their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a report on Wednesday, February 28th. Piper Sandler assumed coverage on TransMedics Group in a research note on Thursday, March 28th. They issued an overweight rating and a $95.00 price target for the company. Finally, JPMorgan Chase & Co. upped their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an overweight rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $119.00.

TransMedics Group Trading Up 2.9 %

TMDX stock opened at $127.99 on Wednesday. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $129.66. The company has a market capitalization of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. The company’s 50-day simple moving average is $85.54 and its 200 day simple moving average is $77.08. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. During the same quarter in the prior year, the business posted ($0.08) EPS. The business’s revenue was up 132.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that TransMedics Group will post 0.54 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 736 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the transaction, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Waleed H. Hassanein sold 56,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total value of $6,475,280.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $8,566,679.81. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 736 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total value of $66,306.24. Following the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 236,378 shares of company stock valued at $23,633,449. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently bought and sold shares of TMDX. Harbour Capital Advisors LLC grew its holdings in shares of TransMedics Group by 1.7% in the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after acquiring an additional 140 shares in the last quarter. RiverPark Advisors LLC boosted its holdings in shares of TransMedics Group by 19.5% in the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock worth $104,000 after buying an additional 215 shares during the last quarter. First Horizon Advisors Inc. grew its position in TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after buying an additional 222 shares during the period. Park Avenue Securities LLC increased its holdings in TransMedics Group by 3.4% during the first quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after buying an additional 372 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in TransMedics Group in the first quarter worth about $30,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.